COVID-19 对银屑病或银屑病关节炎患者的影响。

Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis.

机构信息

P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA.

P. Nash, MBBS, School of Medicine, Griffith University, Nathan, Queensland, Australia.

出版信息

J Rheumatol. 2023 Nov;50(Suppl 2):27-30. doi: 10.3899/jrheum.2023-0521. Epub 2023 Aug 1.

DOI:10.3899/jrheum.2023-0521

PMID:37527863

Abstract

Given the impact of the coronavirus disease 2019 (COVID-19) on patients with psoriatic disease (PsD), a session was devoted at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting to discussing the current understanding of the risk of severe COVID-19 in patients with PsD. The effects of PsD and its treatment on prevention and treatment of COVID-19 with vaccinations, antiviral drugs, and monoclonal antibodies were discussed. The session concluded with a presentation on the perspectives of patient research partners about their experiences with COVID-19.

摘要

鉴于 2019 年冠状病毒病（COVID-19）对银屑病患者（PsD）的影响，在 2022 年 GRAPPA 年会上专门举行了一次会议，讨论目前对 PsD 患者患严重 COVID-19 风险的认识。会议讨论了银屑病及其治疗对疫苗、抗病毒药物和单克隆抗体预防和治疗 COVID-19 的影响。会议最后介绍了患者研究合作伙伴对 COVID-19 经验的看法。